Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Loss Of CTLA-4 Leads To Massive Lymphoproliferation And Fatal Multiorgan Tissue Destruction, Revealing A Critical Negative Regulatory Role Of CTLA-4.

E. Tivol, F. Borriello, A. Schweitzer, W. P. Lynch, J. Bluestone, A. Sharpe
Published 1995 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The B7-CD28/CTLA-4 costimulatory pathway can provide a signal pivotal for T cell activation. Signaling through this pathway is complex due to the presence of two B7 family members, B7-1 and B7-2, and two counterreceptors, CD28 and CTLA-4. Studies with anti-CTLA-4 monoclonal antibodies have suggested both positive and negative roles for CTLA-4 in T cell activation. To elucidate the in vivo function of CTLA-4, we generated CTLA-4-deficient mice. These mice rapidly develop lymphoproliferative disease with multiorgan lymphocytic infiltration and tissue destruction, with particularly severe myocarditis and pancreatitis, and die by 3-4 weeks of age. The phenotype of the CTLA-4-deficient mouse strain is supported by studies that have suggested a negative role for CTLA-4 in T cell activation. The severe phenotype of mice lacking CTLA-4 implies a critical role for CTLA-4 in down-regulating T cell activation and maintaining immunologic homeostasis. In the absence of CTLA-4, peripheral T cells are activated, can spontaneously proliferate, and may mediate lethal tissue injury.
This paper references
10.1126/SCIENCE.1323143
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.
D. Lenschow (1992)
10.1038/336348A0
Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes
S. Mansour (1988)
10.1073/PNAS.90.23.11054
Expression and functional significance of an additional ligand for CTLA-4.
D. Lenschow (1993)
Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
E. Kearney (1995)
CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
G. J. Freeman (1992)
10.1084/JEM.180.6.2049
Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
R. Peach (1994)
10.1126/SCIENCE.7520604
Treatment of murine lupus with CTLA4Ig.
B. Finck (1994)
10.1016/0167-5699(94)90080-9
The B7 and CD28 receptor families.
C. June (1994)
10.1126/SCIENCE.7694363
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
G. Freeman (1993)
10.1016/1074-7613(94)90071-X
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
10.1093/NAR/19.20.5755
The mouse Pgk-1 gene promoter contains an upstream activator sequence.
M. McBurney (1991)
10.1128/JVI.69.3.1408-1419.1995
Induction of focal spongiform neurodegeneration in developmentally resistant mice by implantation of murine retrovirus-infected microglia.
W. P. Lynch (1995)
10.1038/366076A0
B70 antigen is a second ligand for CTLA-4 and CD28
M. Azuma (1993)
10.1016/S1074-7613(94)80021-9
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
P. Linsley (1994)
10.1084/JEM.181.1.351
CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells
H. Schneider (1995)
10.1016/0952-7915(94)90087-6
Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance.
V. Boussiotis (1994)
10.1016/1074-7613(94)90072-8
A negative regulatory function of B7 revealed in B7-1 transgenic mice.
M. P. Sethna (1994)
10.1084/JEM.176.6.1595
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
P. Linsley (1992)
10.1016/0092-8674(92)90611-F
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
E. Li (1992)
10.1126/SCIENCE.7694362
Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
G. Freeman (1993)
10.1016/0092-8674(87)90646-5
Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells
K. Thomas (1987)
Medullary thymic epithelium expresses a ligand for CTLA4 in situ and in vitro.
A. A. Nelson (1993)
10.1038/344742A0
β2-Microglobulin deficient mice lack CD4−8+ cytolytic T cells
M. Zijlstra (1990)
CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.
K. Harper (1991)
10.1084/JEM.178.6.2185
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production
G. Freeman (1993)
10.1172/JCI117982
Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
A. Cross (1995)
10.1073/PNAS.89.22.11102
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
L. A. Turka (1992)
Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.
P. Perrin (1995)
10.1084/JEM.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)



This paper is referenced by
Failure in Patients with Advanced Malignancy A Pilot Study of CTLA-4 Blockade after Cancer Vaccine
Deirdre O’Mahony (2007)
Low-Dose Chemotherapy-treated Tumor-bearing Mice Realization of the Therapeutic Potential of CTLA-4 Blockade in Updated Version
Margalit (2006)
Complex diseases: a genome-wide assessment of the role of selective pressure on the human genome
Roberto Amato (2011)
AutonomousAbsence of CTLA-4 Is Not T Cell Cutting Edge: Lymphoproliferative Disease
Winifred Mak (2015)
10.36290/xon.2017.017
Immunotherapy related toxicities
Aneta Kyllarová (2017)
This information is current as in T Cell-Mediated Colitis Paradoxical Effect of Reduced Costimulation
Gisen Kim (2007)
10.1159/000025347
The Radiation-Sensitive Costimulatory Factors Involved in B-Cell-Dependent T-Cell Activation by Minor Lymphocyte Stimulating Antigen
Kai-ping Chow (1998)
Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-Based Therapeutics
Aaron Prodeus (2018)
10.1245/ASO.2005.08.917
Tumor Regression and Autoimmunity in CytotoxicT Lymphocyte–Associated Antigen 4 Blockade–Treated Patients
PhD Jeffrey S. Weber MD (2005)
The Role of Costimulation in the Persistence of the Immune Response in Kawasaki Disease
Y. Moolani (2010)
10.1097/SLA.0b013e3181f1939d
B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
T. Arigami (2010)
The B7-Independent Isoform of CTLA-4
Melanie Stumpf (2013)
10.1007/s40744-016-0050-2
Osteosarcoma Overview
B. Lindsey (2016)
10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A024257
Immunodeficiency, immunosuppression, and susceptibility to neoplasms.
R. Schwartz (2001)
Tumor immune escape in allogeneic stem cell transplantation: Releasing the brake on graft-versus-tumor immunity
W. J. Norde (2013)
10.1093/ckj/sfw058
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
N. Murakami (2016)
10.1007/978-981-15-6891-6_1
Molecular Mechanism of Lynch Syndrome
K. Tamura (2020)
10.1038/s41423-020-00586-4
Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.
P. Martín (2020)
10.1002/EJI.1830270811
Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor‐transgenic CTLA‐4‐deficient mice
P. Waterhouse (1997)
Cellular and molecular events controlling acquisition of cytotoxic activity by melanoma-reactive CD4⁺ T cells in vivo
Kf Bergerhoff (2016)
10.1016/j.jaut.2016.03.011
Regulatory T cell therapy for type 1 diabetes: May the force be with you.
S. Gitelman (2016)
10.1158/2326-6066.CIR-18-0487
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
A. Young (2018)
10.1073/pnas.0607854103
Modeling CTLA4-linked autoimmunity with RNA interference in mice
Z. Chen (2006)
10.1016/j.jaut.2015.02.004
B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner.
A. Nouël (2015)
10.1053/j.seminoncol.2010.09.005
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
J. Weber (2010)
10.1007/978-0-387-69118-3
Tumor-Induced Immune Suppression
D. Gabrilovich (2008)
10.1016/j.immuni.2019.12.018
Tumor Immunology and Tumor Evolution: Intertwined Histories.
J. Galon (2020)
10.1172/JCI83871
Cancer immunotherapy: harnessing the immune system to battle cancer.
Y. Yang (2015)
Altered expression of T lymphocyte surface markers in children with chronic autoimmune thyroiditis.
A. Kucharska (2008)
The genetic basis of T and B cell contribution to autoimmune diabetes in NOD mice
V. Motta (2006)
This information is current as Function through Multiple Mechanisms Controls Regulatory T Cell Number and Sle 1 a Murine Lupus Susceptibility Locus and
C. Cuda (2007)
10.1385/IR:28:1:49
Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation
Laura L. Carter (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar